Qhov Poob API Ua Haujlwm Zoo Tshaj Plaws rau Koj?
Mar 01, 2026
Tso lus
Taw qhia
Kev tswj hwm kev lag luam thoob ntiaj teb tsis yog qhov yooj yim ntawm "calorie deficits" thiab "willpower." Los ntawm kev xaav ntawm ib tug raw khoom tshwj xeeb ntawmXi'an Tihealth, peb tau hloov mus rau hauv pharmacological Renaissance. Kev nce siab hauv kev thov rau siab -purityActive Pharmaceutical Ingredients (APIs)zoo li GLP-1 agonists thiab NNMT inhibitors tau yuam R & D cov thawj coj saib tshaj li kev lag luam gloss thiab tshuaj xyuas qhov kev ruaj ntseg molecular, impurity profiles, thiab bioavailability ntawm lawv cov khoom siv.
Txawm hais tias koj tab tom tsim cov khoom noj khoom haus zoo tshaj plaws rau lub khw muag khoom lossis cov chaw muag tshuaj rau kev faib khoom loj, qhov "zoo tshaj" API yog lub hom phiaj txav mus. Nyob rau hauv qhov tob tob no, peb tshem tawm qhov hype los tshuaj xyuas qhov tseeb ntawm kev kho mob thiab kev tsim cov logic tom qab hnub no qhov hnyav ua ntej- poob molecules.
Puas yog "Peptide Revolution" tiag tiag qhov kawg -Kev Ua Si rau Kev Kho Mob Obesity?
Yog tias koj tau saib xyuas cov nqi Tshuag ntawm Eli Lilly lossis Novo Nordisk tsis ntev los no, koj paub tiasSemaglutidethiabTirzepatideyog cov titans tam sim no. Tab sis raws li ib tug tub ceev xwm yuav khoom, koj tsis tau yuav Tshuag; koj tab tom yuav kev ua tau zoo thiab ruaj khov.
Semaglutide, GLP-1 receptor agonist, tau hloov pauv qhov "satiety" kev sib tham. Los ntawm kev ua raws li cov tshuaj hormones incretin, nws qhia cov hypothalamus - lub cev metabolic hais kom ua qhov chaw - tias lub tank puv. Los ntawm kev pom ntawm lub chaw kuaj mob, kev sib txuas ntawm Semaglutide yog daim duab kos duab. NtawmXi'an Tihealth, peb hais txog tias "99% purity" ntawm COA (Certificate of Analysis) feem ntau yog cov hauv paus ntsiab lus, tsis yog lub cim ntawm kev hwm. Qhov kev sib tw tiag tiag yog nyob rau hauv 1% ntawm impurities-sab- chain truncations thiab residual solvents uas tuaj yeem cuam tshuam lub txee- lub neej ntawm koj qhov kawg txhaj tshuaj los yog qhov ncauj formulation.
Tirzepatide ua qhov no ib kauj ruam ntxiv raws li ob GLP-1/GIP agonist. Nws tsis cia li suppress qab los noj mov; Nws txhim kho li cas lub cev tswj cov piam thaj thiab lipids. Txawm li cas los xij, ntawm no yog qhov tseeb "sab hauv": cov peptides no yog "divas." Lawv xav tau kev tswj qhov kub thiab txias thiab muaj kev cuam tshuam rau kev ntxhov siab thaum lub sijhawm tsim khoom. Yog tias koj lub chaw tsis tau nruab rau kev ua haujlwm siab -peptide tuav, koj tsis yog poob nyiaj xwb-koj poob peev xwm.
Vim li cas Orlistat pheej pheej thaum niaj hnub Peptides muab yuag ntau dua?
Nws yog ib qho yooj yim kom tso tsegOrlistatraws li "laus thev naus laus zis," tab sis qhov ntawd yuav yog qhov yuam kev rau txhua tus neeg yuav khoom B2B tsom rau OTC (Tshaj - lub -Counter) kev lag luam. Thaum peptides tsom rau lub hlwb, Orlistat tsom rau lub phaj.
Raws li lub plab thiab pancreatic lipase inhibitor, Orlistat ua haujlwm hauv zos hauv GI ib puag ncig. Nws tiv thaiv kwv yees li 30% ntawm cov khoom noj muaj roj los ntawm kev nqus. Kev zoo nkauj ntawm Orlistat los ntawm kev tswj hwm txoj cai yog nws qhov profile kev nyab xeeb. Vim tias nws tsis yog qhov systemic- txhais tau tias nws tsis nkag mus rau hauv cov hlab ntsha - qhov kev pheej hmoo ntawm kev puas siab puas ntsws lossis cov hlab plawv yog qhov tsis zoo.
Rau ntau ntawm peb cov neeg siv khoom ntawm Xi'an Tihealth, Orlistat tseem yog ib qho tseem ceeb vim nws yogmuaj zog. Koj tuaj yeem ntim nws, ntim nws, thiab xa nws mus rau qhov chaw sov tsis muaj kev txhawj xeeb txog cov saw txias. Yog lawm, "cov xwm txheej hauv plab" (peb txhua tus tau hnov cov dab neeg hais txog cov quav muaj roj) yog qhov tsis zoo, tab sis rau cov neeg siv khoom uas xav tau cov tshuaj tsis yog -invasive, tsis yog - txhaj tshuaj, Orlistat tseem yog huab tais ntawm lub khw muag khoom txee.
Tus Tshiab "Triple-Agonist" Retatrutide puas tuaj yeem daws qhov Metabolic Plateau?
Qhov kev tsis txaus siab tshaj plaws los ntawm cov neeg mob ntawm qhov poob phaus APIs yog "plateau"- lub sijhawm uas lub cev tawm tsam thiab poob phaus. Nkag musRetatrutide, triple agonist (GLP-1, GIP, thiab Glucagon receptors).
Hauv peb qhov kev ntsuam xyuas, Retatrutide yog "dav dav hlau" ntawm APIs. Qhov sib ntxiv ntawm glucagon receptor agonism yog ci ntsa iab - nws nce kev siv hluav taws xob. Thaum lwm tus ob agonists txwv koj los ntawm kev noj mov, glucagon tivthaiv yuam lub cev kom hlawv qhov nws twb muaj lawm.
Rau R & D department, Retatrutide sawv cev rau qib siab tshaj plaws ntawm kev nyuaj. Nws xav tau kev nkag siab zoo ntawm receptor affinity. Puas muaj zog heev? Tej zaum rau cov neeg noj zaub mov zoo li qub. Tab sis rau kev kho mob - qib kev ua lag luam, nws sawv cev rau yav tom ntej ntawm cov tshuaj metabolic. Ntawm Tihealth, peb saib cov molecule no tsis yog raws li cov khoom lag luam, tab sis ua pov thawj rau qhov kev sib txuas ntawm peptide tau los txij li thaum peb tsim xyoo 2008.
Puas yog 5-Amino-1MQ Cov riam phom zais cia rau "Muscle-Sparing" Fat Poob?
Ib qho ntawm "kev qias neeg me me" ntawm kev poob phaus sai yog sarcopenia- poob ntawm cov leeg nqaij nrog rau cov rog. Qhov no yog qhov twg5-Amino-1MQnkag mus rau hauv kev sib tham, tshwj xeeb tshaj yog rau high -kawg nutraceutical thiab kis las khoom noj khoom haus sectors.
Tsis zoo li GLP-1 tsev neeg, 5-Amino-1MQ yog ib qho me me molecule uas inhibitsNNMT (nicotinamide N{0}}methyltransferase). Qhov no enzyme yog ib tug metabolic nres; thaum koj inhibit nws, koj nce NAD + thiab SAM qib hauv cov rog rog, zoo "rewiring" lawv kom hlawv roj.
Qhov kev thov rov hais dua ntawm no yog lub cev muaj pes tsawg leeg. Nws tsis tsuas yog ua rau tus lej ntawm qhov ntsuas qis; nws tsom cov roj visceral thaum khaws cov nqaij mos. Rau peb cov neeg koom tes B2B hauv "Lub Cev Kom Zoo" lossis "Longevity" niches, qhov no yog qhov muag zoo nkauj dua li cov tshuaj uas tawm hauv cov neeg siv "skinny- rog.
Yuav Ua Li Cas Peb Taug Kev Minefield ntawm API Zoo thiab Ua Tau Zoo?
Wb hais lus ncaj ncees. Lub khw yog dej nyab nrog "pheej yig" APIs. Yog tias koj tshawb xyuas lub vev xaib, koj yuav pom ntau pua tus neeg muag khoom cog lus rau lub ntiaj teb ntawm ib nrab ntawm tus nqi lag luam. Raws li tus kws tshawb fawb, qhov no ua rau kuv nyob hmo ntuj.
API "low-purity" tsis tsuas yog ua haujlwm tsawg; nws yog kev lav ris. Residual TFA (Trifluoroacetic acid), cov hlau hnyav, lossis cov kab mob microbial endotoxins tuaj yeem ua rau cov khoom lag luam puas thaum hmo ntuj. NtawmXi'an Tihealth, peb daim ntawv pov thawj ISO9001: 2015 tsis yog ib qho plaque ntawm phab ntsa xwb; nws yog peb cov DNA ua haujlwm. Peb kho txhua gram ntawm cov khoom zoo li nws tau mus rau hauv cov khoom rau peb tsev neeg.
Thaum koj ntsuas tus neeg xa khoom, nug rau qhovHPLC thiab MS (Mass Spectrometry)qhia. Yog lawv tsis kam, taug kev mus. Hauv ntiaj teb B2B, koj tus neeg muag khoom yog koj tus khub tseem ceeb tshaj plaws. Peb tsis yog muab hmoov xwb; peb muab cov ntaub ntawv thiab kev thaj yeeb ntawm lub siab tias koj cov qauv yuav dhau qhov thib peb - tog neeg soj ntsuam.
Puas yog Hybrid Formulations yav tom ntej ntawm kev lag luam poob phaus?
Peb tab tom pom qhov sib txawv loj heev rau "API + Botanical" kev sib koom ua ke. Vim li cas siv rab rauj thaum koj tuaj yeem siv scalpel?
Ntau ntawm peb cov neeg siv khoom siv tau zoo sib txuas ua ke qis dua ntawm API muaj zog zoo liSemaglutidenrog siab -purityBerberine HCLlos yogGreen Tea Extract (EGCG). Qhov "stacking" txoj hauv kev no tuaj yeem txo cov kev mob tshwm sim thaum tswj kev ua tau zoo. Nws kuj tseem tso cai rau ntau "natural" kev lag luam lub kaum ntse ntse, uas yog qhov tseem ceeb rau kev lag luam tshuaj pleev ib ce thiab khoom noj khoom haus.
|
API / Molecule |
Mechanism |
Qhov tseem ceeb tshaj |
Zoo tshaj rau |
|
Semaglutide |
GLP-1 Agonist |
Qhov hnyav txo |
Clinical Obesity |
|
Tirzepatide |
GLP-1/GIP Agonist |
Superior glucose tswj |
Mob ntshav qab zib + poob phaus |
|
Orlistat |
Lipase Inhibitor |
Zero systemic absorption |
OTC Cov Khoom Muag Khoom Muag |
|
5-Amino-1MQ |
NNMT Inhibitor |
Kev khaws cia nqaij |
Kev Ua Si / Anti-Aging |
|
Retatrutide |
Triple Agonist |
Siab tshaj plaws metabolic hlawv |
Advanced R & D |
Kev xav zaum kawg: Txoj kev twg yuav tsum koj lub hom phiaj coj?
Qhov "zoo tshaj" qhov hnyav API tsis pom nyob rau hauv phau ntawv; nws tau pom ntawm qhov sib tshuam ntawm koj lub hom phiaj cov neeg siv khoom xav tau thiab koj lub peev xwm tsim khoom.
Yog koj xav tauunmatched kev ua tau zoo, GLP-1 / GIP peptides yog koj tus qauv kub.
Yog koj xav taukev tswj hwm kev nyab xeeb thiab huab hwm coj- kev lag luam ncav cuag, Orlistat yog koj tus neeg ua haujlwm.
Yog koj xav tauinnovate nyob rau hauv lub Fitness niche, 5-Amino-1MQ yog koj ntug.
NtawmXi'an Tihealth Biotechnology, peb tau siv sijhawm ze li ob xyoo caum los txuas qhov sib txawv ntawm cov peev txheej molecular thiab ua tiav - khoom zoo. Peb caw koj los kho peb tsis yog tus neeg muag khoom, tab sis raws li kev txuas ntxiv ntawm koj tus kheej R & D pab neeg.
Cov ntaub ntawv
Wilding, JPH, thiab al. (2021). Ib zaug -Semaglutide txhua lub limtiam hauv cov neeg laus uas hnyav dhau lossis rog. New England Journal of Medicine.
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Knerr, PJ, et al. (2023). Cov qauv thiab kev ua haujlwm ntawm rettrutide (LY3437943), triagonist ntawm glucagon, GIP, thiab GLP-1 receptors. Cell Metabolism.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00212-X
Guerrieri, D., et al. (2000). Kev ua tau zoo thiab kev nyab xeeb ntawm orlistat hauv kev tswj cov neeg mob rog. Pharmacological tshawb fawb.
https://pubmed.ncbi.nlm.nih.gov/10884333/
Neubauer, K., et al. (2019). Lub luag haujlwm ntawm NNMT hauv cov kab mob metabolic thiab nws lub peev xwm ua lub hom phiaj kho mob. Ntuj Metabolism.
https://www.nature.com/articles/s42255-019-0079-x
He, JP, et al. (2024). Me me molecule NNMT inhibitors: Ib tug tshiab frontier nyob rau hauv sarcopenia thiab rog. Biochemical Pharmacology.
https://www.sciencedirect.com/science/article/abs/pii/S000629522400123X
Xa kev nug